Page 29 - 2021_04-Haematologica-web

Fecal microbial transplant in HSCT
Colonization with multidrug-resistant bac- teria increases the risk of complications and a fatal outcome after allogeneic hematopoi- etic cell transplantation. Ann Hematol. 2018;97(3):509-517.
62. Bilinski J, Robak K, Peric Z, et al. Impact of gut colonization by antibiotic-resistant bac- teria on the outcomes of allogeneic hematopoietic stem cell transplantation: a retrospective, single-center study. Biol Blood Marrow Transplant. 2016;22(6):1087-1093.
63. Oren I, Sprecher H, Finkelstein R, et al. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colo- nization with nonabsorbable oral antibiotic treatment: a prospective controlled trial. Am J Infect Control. 2013;41(12):1167-1172.
64. Battipaglia G, Malard F, Rubio MT, et al. Fecal microbiota transplantation before or after allogeneic hematopoietic transplanta- tion in patients with hematologic malignan- cies carrying multidrug-resistance bacteria. Haematologica. 2019;104(8):1682-1688.
65.Innes AJ, Mullish BH, Fernando F, et al. Faecal microbiota transplant: a novel biolog- ical approach to extensively drug-resistant organism-related non-relapse mortality. Bone Marrow Transplant. 2017;52(10):1452- 1454.
66. Malard F, Vekhoff A, Lapusan S, et al. The ODYSSEE study: Prevention of dysbiosis complications with autologous fecal micro- biota transfer in acute myeloid leukemia patients undergoing intensive-treatment: Results of a prospective multicenter trial. Bone Marrow Transplant. 2019;54:OS16-11
67.Willems L, Porcher R, Lafaurie M, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: inci- dence, risk factors, and outcome. Biol Blood Marrow Transplant. 2012;18(8):1295-1301.
68. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54(8):1053-1063.
69. Dubberke ER, Reske KA, Olsen MA, et al. Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoiet- ic cell and lung transplant recipients. Transpl Infect Dis. 2018;20(2):e12855.
70. Kinnebrew MA, Lee YJ, Jenq RR, et al. Early Clostridium difficile infection during allo- geneic hematopoietic stem cell transplanta- tion. PLoS One. 2014;9(3):e90158.
71. Webb BJ, Brunner A, Ford CD, Gazdik MA, Petersen FB, Hoda D. Fecal microbiota trans- plantation for recurrent Clostridium difficile infection in hematopoietic stem cell trans- plant recipients. Transpl Infect Dis. 2016;18(4):628-633.
72. Moss EL, Falconer SB, Tkachenko E, et al. Long-term taxonomic and functional diver- gence from donor bacterial strains following fecal microbiota transplantation in immuno- compromised patients. PLoS One. 2017;12(8):e0182585.
73. Bluestone H, Kronman MP, Suskind DL. Fecal microbiota transplantation for recur- rent Clostridium difficile infections in pedi- atric hematopoietic stem cell transplant recipients. J Pediatric Infect Dis Soc. 2018;7(1):e6-e8.
74. Han L, Zhang H, Chen S, et al. Intestinal microbiota can predict acute graft-versus- host disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(10): 1944-1955.
75.Kroger N, Iacobelli S, Franke GN, et al. Dose-reduced versus standard conditioning
followed by allogeneic stem-cell transplan- tation for patients with myelodysplastic syndrome: A Prospective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncol. 2017;35(19):2157-2164.
76. Scott BL. Long-Term Follow up of BMT CTN 0901, a randomized phase III trial comparing myeloablative (MAC) to reduced intensity conditioning (RIC) prior to hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) or myelodysplasia (MDS) (MAvRIC Trial). Biol Blood Marrow Transplant. 2020;26(3):S11.
77. Sengsayadeth S, Gatwood KS, Boumendil A, et al. Conditioning intensity in secondary AML with prior myelodysplastic syn- drome/myeloproliferative disorders: an EBMT ALWP study. Blood Adv. 2018;2(16): 2127-2135.
78. D'Amico F, Biagi E, Rampelli S, et al. Enteral nutrition in pediatric patients undergoing hematopoietic SCT promotes the recovery of gut microbiome homeostasis. Nutrients. 2019;11(12):2958.
79. Venkataraman A, Sieber JR, Schmidt AW, Waldron C, Theis KR, Schmidt TM. Variable responses of human microbiomes to dietary supplementation with resistant starch. Microbiome. 2016;4(1):33.
80. Riwes MM, Schmidt A, Braun T, et al. Rational modification of intestinal microbio- me and metabolites after allogeneic hematopoietic stem cell transplantation with resistant starch: a pilot study. Blood. 2019;134(Suppl_1):3276.
81.Gorshein E, Wei C, Ambrosy S, et al. Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoiet- ic stem cell transplantation. Clin Transplant. 2017;31(5).
82. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256- 1264; quiz 1446-1257.
83. Stein-Thoeringer CK, Nichols KB, Lazrak A, et al. Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science. 2019;366(6469):1143-1149.
84. Khandelwal P, Andersen H, Romick- Rosendale L, et al. A pilot study of human milk to reduce intestinal inflammation after bone marrow transplant. Breastfeed Med. 2019;14(3):193-202.
85.Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infec- tions in afebrile neutropenic patients follow- ing chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.
86.Tomblyn M, Brunstein C, Burns LJ, et al. Similar and promising outcomes in lym- phoma patients treated with myeloablative or nonmyeloablative conditioning and allo- geneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14(5): 538-545.
87. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibac- terial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98(12):1826-1835. Weber D, Oefner PJ, Hiergeist A, et al. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbio- me and are associated with poor outcome. Blood. 2015;126(14):1723-1728.
89.Weber D, Hiergeist A, Weber M, et al. Detrimental Effect of broad-spectrum
antibiotics on intestinal microbiome diversi- ty in patients after allogeneic stem cell trans- plantation: lack of commensal sparing antibiotics. Clin Infect Dis. 2019;68(8):1303- 1310.
90. Routy B, Letendre C, Enot D, et al. The influence of gut-decontamination prophy- lactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation. Oncoimmunology. 2017;6(1):e1258506.
91. Weber D, Jenq RR, Peled JU, et al. Microbiota disruption induced by early use of broad-spectrum antibiotics is an inde- pendent risk factor of outcome after allo- geneic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(5):845-852.
92. Morjaria S, Schluter J, Taylor BP, et al. Antibiotic-induced shifts in fecal microbiota density and composition during hematopoi- etic stem cell transplantation. Infect Immun. 2019;87(9):e00206-e00219.
93. Simms-Waldrip TR, Sunkersett G, Coughlin LA, et al. Antibiotic-induced depletion of anti-inflammatory Clostridia is associated with the development of graft-versus-host disease in pediatric stem cell transplantation patients. Biol Blood Marrow Transplant. 2017;23(5):820-829.
94. Lee SE, Lim JY, Ryu DB, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2019;25(10): 1933-1943.
95.Shono Y, Docampo MD, Peled JU, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allo- geneic hematopoietic stem cell transplanta- tion in human patients and mice. Sci Transl Med. 2016;8(339):339ra371.
96. Romick-Rosendale LE, Haslam DB, Lane A, et al. Antibiotic exposure and reduced short chain fatty acid production after hematopoi- etic stem cell transplant. Biol Blood Marrow Transplant. 2018;24(12):2418-2424.
97. Nishi K, Kanda J, Hishizawa M, et al. Impact of the Use and type of antibiotics on acute graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24(11):2178-2183.
98. Spindelboeck W, Schulz E, Uhl B, et al. Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host- disease. Haematologica. 2017;102(5):e210- e213.
99. Kaito S, Toya T, Yoshifuji K, et al. Fecal microbiota transplantation with frozen cap- sules for a patient with refractory acute gut graft-versus-host disease. Blood Adv. 2018;2(22):3097-3101.
100. Zhang J, Ren G, Li M, Lu P, Yi S. The effects of fecal donors with different feeding pat- terns on diarrhea in a patient undergoing hematopoietic stem cell transplantation. Case Rep Hematol. 2019;2019:4505238.
101. Zhong S, Zeng J, Deng Z, et al. Fecal micro- biota transplantation for refractory diarrhea in immunocompromised diseases: a pedi- atric case report. Ital J Pediatr. 2019;45 (1):116.
102.Shouval R, Youngster I, Geva M, et al. Repeated courses of orally administered fecal microbiota transplantation for the treatment of steroid resistant and steroid dependent intestinal acute graft vs. host dis- ease: A pilot study (NCT 03214289). Blood. 2018;132(Suppl_1):2121.
103.Malard F, Legrand F, Cornillon J, et al. Successful and safe treatment of intestinal
88.
haematologica | 2021; 106(4)
945